Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 131 to 140 of 331

TitleReference numberPublishedLast updated
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Immunoscore for predicting risk of colon cancer relapseMIB269
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
trublood-prostate for triaging and diagnosing people with prostate cancer symptomsMIB268
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712

Results per page

  1. 10
  2. 25
  3. 50
  4. All